1. Ticagrelor was non-inferior to DAPT for the incidence of major adverse cardiovascular and cerebrovascular events. 2. Ticagrelor monotherapy significantly ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
1. The ARAMIS trial revealed that the rate of favourable neurologic function at 90 days was 93.8% among patients assigned ...
1. In this secondary analysis of the HOST-EXAM randomized clinical trial, clopidogrel monotherapy was associated with lower rates of the ...
1. The composite of MRI-detected brain infarcts and symptomatic ischemic stroke was comparable across different doses of asundexian and placebo. ...
1. Treatment after a minor stroke or transient ischemic attack with dual anti-platelet therapy (DAPT), either clopidogrel with aspirin or ...
1. Abbreviated antiplatelet therapy was shown to be noninferior to the standard duration of therapy in net adverse clinical and ...
![Novel biodegradable sirolimus-eluting stents non-inferior to durable everolimus-eluting stents [BIOSCIENCE trial]](https://www.2minutemedicine.com/wp-content/uploads/2014/09/Taxus_stent_FDA-e1607803635904-350x250.jpg)
1. Guided selection of antiplatelet therapy reduced rates of major adverse cardiovascular event rates compared to standard therapy. 2. Guided ...
1. There was no significant difference in periprocedural myonecrosis between ticagrelor and clopidogrel among patients undergoing high-risk elective PCI. 2. ...
1. After successful transcatheter aortic valve replacement, compared to an anti-platelet based strategy, patients that received an anti-coagulation strategy including ...
